Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-608 in Ankylosing Spondylitis
NCT06242652Phase 2Active, not recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 608 in ankylosing spondylitis (AS), sponsored by 3S Guojian Pharmaceutical. Started Mar 2024; status: active, not recruiting.
02
Drugs
608
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT06242652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242652.